Publications

1. Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

   Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

   Letter | 21-12-2020

2. GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

   The National Health Care Institute has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product ...

   Report | 16-12-2020

3. GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections

   Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...

   Report | 15-12-2020

4. GVS assessment - extension of further conditions for nintedanib (Ofev®)

   The National Health Care Institute has completed its assessment of the possible extension of the further conditions for ...

   Report | 15-12-2020

5. Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL

   Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...

   Report | 10-12-2020

6. GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis

   The National Health Care Institute has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or ...

   Report | 03-12-2020

7. Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy

   Zorginstituut Nederland recommends that ataluren be designated as a potential candidate for conditional inclusion. Ataluren is ...

   Letter | 24-11-2020

8. GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis

   The National Health Care Institute has completed its assessment whether siponimod (Mayzent®) is interchangeable with a product ...

   Report | 16-11-2020

9. Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

   The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) in combination with obinutuzumab ...

   Report | 16-11-2020

10. GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia

    The National Health Care Institute has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of ...

    Report | 05-11-2020